Mae cyngor AWMSG mewn perthynas â Kalydeco wedi ystyried materion effeithiolrwydd cost a’r data sydd ar gael o dreialon clinigol. O ystyried mai cyfyngedig yw’r data, a bod y costau’n uchel – tua £180,000 y claf y flwyddyn – mae’r rhain yn ystyriaethau priodol iawn. Fodd bynnag, mae materion cydraddoldeb yn yr achos hwn yn fy arwain i’r casgliad bod yn rhaid canfod ffordd o ddarparu Kalydeco drwy GIG Cymru i’r cleifion cymwys hynny â ffibrosis systig. Rwy’n cael ar ddeall bod 13 o gleifion cymwys yng Nghymru ar hyn o bryd ac rwy’n cadarnhau y bydd Kalydeco ar gael i’r unigolion hyn. Mae gwaith bellach wedi cychwyn ar y manylion ar gyfer cyflwyno’r feddyginiaeth.
AWMSG’s advice in relation to Kalydeco will have taken into account issues of cost effectiveness and available clinical trial data.  Given that data is limited, and costs are high – at some £180,000 per patient per year, these are very proper considerations.  Issues of equity in this case, however, lead me to conclude that a way must be found to provide Kalydeco within NHS Wales for those eligible patients with cystic fibrosis.  I am currently advised that there are in the region of 13 eligible patients in Wales and I confirm Kalydeco will be available for these individuals.   Work on the detail of its introduction  is now underway.